

Noriko Motoi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1004331/publications.pdf>

Version: 2024-02-01

192
papers

9,854
citations

101496

36
h-index

37183

96
g-index

193
all docs

193
docs citations

193
times ranked

12356
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	3.3	1,557
2	Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine, 2008, 14, 822-827.	15.2	1,015
3	Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Modern Pathology, 2011, 24, 653-664.	2.9	866
4	Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. Journal of Clinical Investigation, 2007, 117, 3846-3856.	3.9	574
5	EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology, 2009, 22, 508-515.	2.9	429
6	Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis. American Journal of Surgical Pathology, 2008, 32, 810-827.	2.1	352
7	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2017, 35, 3867-3876.	0.8	343
8	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. Cancer Science, 2019, 110, 1480-1490.	1.7	238
9	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	0.5	234
10	Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease. American Journal of Surgical Pathology, 2014, 38, 448-460.	2.1	214
11	Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Modern Pathology, 2012, 25, 1574-1583.	2.9	206
12	An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene, 2009, 28, 2773-2783.	2.6	205
13	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
14	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203
15	Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Modern Pathology, 2017, 30, 797-809.	2.9	149
16	Long noncoding RNA <i>HOTAIR</i> is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer. Cancer Medicine, 2014, 3, 632-642.	1.3	130
17	P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. EBioMedicine, 2016, 3, 54-66.	2.7	123
18	Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1788-1797.	0.5	115

#	ARTICLE	IF	CITATIONS
19	The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 334-346.	0.5	113
20	EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 527-534.e1.	1.1	108
21	Intrinsic Cooperation between p16INK4a and p21Waf1/Cip1 in the Onset of Cellular Senescence and Tumor Suppression <i>in vivo</i> . <i>Cancer Research</i> , 2010, 70, 9381-9390.	0.4	107
22	Pulmonary fibrosis in an individual occupationally exposed to inhaled indium-tin oxide. <i>European Respiratory Journal</i> , 2005, 25, 200-204.	3.1	106
23	Identification of DOK genes as lung tumor suppressors. <i>Nature Genetics</i> , 2010, 42, 216-223.	9.4	105
24	Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin. <i>Pathology Research and Practice</i> , 2000, 196, 1-7.	1.0	96
25	Clinical features and high-resolution CT findings of pulmonary cryptococcosis in non-AIDS patients. <i>Respiratory Medicine</i> , 2006, 100, 807-812.	1.3	80
26	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. <i>Cancer Cytopathology</i> , 2019, 127, 325-339.	1.4	78
27	Cyclosporin Treatment in Steroid-resistant and Acutely Exacerbated Interstitial Pneumonia. <i>Internal Medicine</i> , 2005, 44, 1144-1150.	0.3	75
28	High-Resolution Computed Tomography Findings of Lung Cancer Associated With Idiopathic Pulmonary Fibrosis. <i>Journal of Computer Assisted Tomography</i> , 2006, 30, 95-99.	0.5	73
29	Small lung tumors with the size of 1cm or less in diameter: clinical, radiological, and histopathological characteristics. <i>Lung Cancer</i> , 2004, 44, 43-51.	0.9	67
30	Long-Term Prognosis of Patients With Resected Adenocarcinoma In Situ and Minimally Invasive Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1312-1320.	0.5	64
31	Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report. <i>Thoracic Cancer</i> , 2019, 10, 1285-1288.	0.8	58
32	Fulminant Septicemic Syndrome of <i>Bacillus cereus</i> in a Leukemic Patient.. <i>Internal Medicine</i> , 1997, 36, 221-226.	0.3	57
33	Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 179-188.	0.9	56
34	Insulinoma-associated Protein 1 (INSM1) Is a Better Marker for the Diagnosis and Prognosis Estimation of Small Cell Lung Carcinoma Than Neuroendocrine Phenotype Markers Such as Chromogranin A, Synaptophysin, and CD56. <i>American Journal of Surgical Pathology</i> , 2020, 44, 757-764.	2.1	48
35	Acinar Cell Carcinoma of the Pancreas with Intraductal Growth: Report of a Case. <i>Pancreas</i> , 2003, 26, 306-308.	0.5	47
36	Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2016, 93, 43-46.	0.9	47

#	ARTICLE	IF	CITATIONS
37	Chondrosarcoma of the hand secondary to multiple enchondromatosis; report of two cases. Archives of Orthopaedic and Trauma Surgery, 2003, 123, 42-47.	1.3	35
38	Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin. Medicine (United States), 2015, 94, e2324.	0.4	33
39	Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern. Journal of Thoracic Oncology, 2016, 11, 2141-2149.	0.5	33
40	Intracortical chondroblastoma mimicking intra-articular osteoid osteoma. Skeletal Radiology, 2002, 31, 603-607.	1.2	32
41	Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study. Melanoma Research, 2020, 30, 76-84.	0.6	32
42	A subset of small cell lung cancer with low neuroendocrine expression and good prognosis: a comparison study of surgical and inoperable cases with biopsy. Human Pathology, 2014, 45, 1045-1056.	1.1	31
43	Pigmented neurofibroma: review of Japanese patients with an analysis of melanogenesis demonstrating coexpression of c-met protooncogene and microphthalmia-associated transcription factor. Human Pathology, 2005, 36, 871-877.	1.1	30
44	Risk factors for distant metastasis of dermatofibrosarcoma protuberans. Journal of Orthopaedics and Traumatology, 2016, 17, 261-266.	1.0	30
45	Clinical Features of Ground Glass Opacityâ€œDominant Lung Cancer Exceeding 3.0 cm in the Whole Tumor Size. Annals of Thoracic Surgery, 2018, 105, 1499-1506.	0.7	29
46	Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 2078-2090.	0.5	29
47	CD20 ⁺ tumorâ€œinfiltrating immune cells and CD204 ⁺ M2 macrophages are associated with prognosis in thymic carcinoma. Cancer Science, 2020, 111, 1921-1932.	1.7	28
48	Prognostic Significance of Tumor Size of Small Lung Adenocarcinomas Evaluated with Mediastinal Window Settings on Computed Tomography. PLoS ONE, 2014, 9, e110305.	1.1	27
49	High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wildâ€œtype epidermal growthâ€œfactor receptor cases. Pathology International, 2017, 67, 37-44.	0.6	27
50	Comparative Clinicopathology of Obliterative Bronchiolitis and Diffuse Panbronchiolitis. Respiration, 2006, 73, 481-487.	1.2	25
51	Whole-exome and RNA sequencing of pulmonary carcinoid reveals chromosomal rearrangements associated with recurrence. Lung Cancer, 2020, 145, 85-94.	0.9	25
52	Primary leiomyosarcoma of the femur. Journal of Orthopaedic Science, 2002, 7, 267-273.	0.5	23
53	Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma. Cancer Science, 2016, 107, 320-325.	1.7	22
54	Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis. BMC Cancer, 2016, 16, 750.	1.1	22

#	ARTICLE	IF	CITATIONS
55	Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 4154-4165.	1.7	22
56	Pulmonary Carcinoids and Low-Grade Gastrointestinal Neuroendocrine Tumors Show Common MicroRNA Expression Profiles, Different from Adenocarcinomas and Small Cell Carcinomas. <i>Neuroendocrinology</i> , 2018, 106, 47-57.	1.2	21
57	Necrotizing <i>Bacillus cereus</i> infection of the meninges without inflammatory reaction in a patient with acute myelogenous leukemia: a case report. <i>Acta Neuropathologica</i> , 1997, 93, 301-305.	3.9	20
58	Deleterious Pulmonary Surfactant System Gene Mutations in Lung Adenocarcinomas Associated With Usual Interstitial Pneumonia. <i>JCO Precision Oncology</i> , 2018, 2, 1-24.	1.5	20
59	Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 815-822.	0.8	20
60	Malignant T-cell lymphoma of the thyroid gland associated with Hashimoto's thyroiditis. <i>Pathology International</i> , 2005, 55, 425-430.	0.6	19
61	A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-small Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1818-1827.	0.5	18
62	Lymph Node Metastases and Prognosis in Left Upper Division Non-Small Cell Lung Cancers: The Impact of Interlobar Lymph Node Metastasis. <i>PLoS ONE</i> , 2015, 10, e0134674.	1.1	18
63	Dedifferentiated chondrosarcoma of the rib with a malignant mesenchymatous component: An autopsy case report. <i>Pathology International</i> , 1997, 47, 397-403.	0.6	17
64	Early evaluation of the therapeutic effect of denosumab on tartrate-resistant acid phosphatase 5b expression in a giant cell tumor of bone: a case report. <i>BMC Research Notes</i> , 2014, 7, 608.	0.6	17
65	Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 140, 28-36.	1.3	17
66	Pharmacological blockage of transforming growth factor- β 2 signalling by a Traf2- and Nck-interacting kinase inhibitor, NCB-0846. <i>British Journal of Cancer</i> , 2021, 124, 228-236.	2.9	17
67	A Case of Concurrent Sarcoidosis, Aortitis Syndrome and Crohn's Disease. <i>Internal Medicine</i> , 2011, 50, 2915-2917.	0.3	16
68	A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1638-1646.	0.5	16
69	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. <i>Medical Oncology</i> , 2019, 36, 49.	1.2	16
70	Ciliated Muconodular Papillary Tumor of the Lung: Thin-Section CT Findings of 16 Cases. <i>American Journal of Roentgenology</i> , 2020, 214, 761-765.	1.0	16
71	Bilateral choroidal metastases secondary to uterocervical carcinoma of the squamous cell type. <i>American Journal of Ophthalmology</i> , 2000, 130, 682-684.	1.7	15
72	Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations. <i>Lung Cancer</i> , 2011, 74, 401-404.	0.9	15

#	ARTICLE	IF	CITATIONS
73	Actinin-4 protein overexpression as a predictive biomarker in adjuvant chemotherapy for resected lung adenocarcinoma. <i>Biomarkers in Medicine</i> , 2017, 11, 721-731.	0.6	15
74	Cryobiopsy during flex-rigid pleuroscopy: an emerging alternative biopsy method in malignant pleural mesothelioma. A comparative study of pathology. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 559-566.	0.6	15
75	Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and Japanese Society of Clinical Cytology: An Interobserver Reproducibility Study and Risk of Malignancy Evaluation on Cytology Specimens. <i>Acta Cytologica</i> , 2020, 64, 452-462.	0.7	15
76	Elastin in pulmonary pathology: relevance in tumours with a lepidic or papillary appearance. A comprehensive understanding from a morphological viewpoint. <i>Histopathology</i> , 2022, 80, 457-467.	1.6	15
77	Incidence of Pneumothorax in Advanced and/or Metastatic Soft Tissue Sarcoma Patients during Pazopanib Treatment. <i>Clinical Oncology</i> , 2014, 26, 357.	0.6	14
78	Osteosarcoma arising in fibrous dysplasia, confirmed by mutational analysis of GNAS gene. <i>Pathology Research and Practice</i> , 2018, 214, 318-324.	1.0	14
79	<scp>HSP90</scp> inhibition overcomes <scp><i>EGFR</i></scp> amplification-induced resistance to third-generation <scp>EGFR-TKIs</scp>. <i>Thoracic Cancer</i> , 2021, 12, 631-642.	0.8	14
80	Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 162, 1-10.	1.3	14
81	Sonographic findings in three cases of carcinoma showing thymus-like differentiation. <i>Journal of Clinical Ultrasound</i> , 2013, 41, 574-578.	0.4	13
82	Differences in the responses to pazopanib and the prognoses of soft tissue sarcomas by their histological eligibility for the PALETTE study. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 449-455.	0.6	13
83	Primary pulmonary meningioma: A rare case report of aspiration cytological features and immunohistochemical assessment. <i>Diagnostic Cytopathology</i> , 2019, 47, 330-333.	0.5	13
84	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
85	Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions. <i>Scientific Reports</i> , 2021, 11, 18762.	1.6	13
86	Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>Lung Cancer</i> , 2021, 159, 128-134.	0.9	13
87	Pulmonary Adenocarcinoma In Situ. <i>American Journal of Surgical Pathology</i> , 2015, 39, 912-921.	2.1	12
88	Ciliated muconodular papillary tumor of the lung: 18F-FDG PET/CT findings of 15 cases. <i>Annals of Nuclear Medicine</i> , 2020, 34, 448-452.	1.2	12
89	Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma. <i>Lung Cancer</i> , 2020, 145, 158-166.	0.9	11
90	Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment. <i>British Journal of Cancer</i> , 2021, 124, 925-932.	2.9	10

#	ARTICLE	IF	CITATIONS
91	Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients. <i>Clinical Lung Cancer</i> , 2022, 23, 477-486.	1.1	10
92	Spindle cell lipoma of the knee: a case report. <i>Journal of Orthopaedic Science</i> , 2004, 9, 86-89.	0.5	9
93	Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥50%) NSCLC. <i>Clinical Lung Cancer</i> , 2021, 22, 127-133.e3.	1.1	9
94	Rounded Atelectasis Associated with Pulmonary Lymphangioleiomyomatosis. <i>Internal Medicine</i> , 2005, 44, 625-627.	0.3	8
95	Cytopathological review of patients that underwent thyroidectomies based on the diagnosis of papillary thyroid carcinoma by fine needle aspiration cytology but were later found to have benign tumors by histopathology. <i>Surgery Today</i> , 2013, 43, 632-637.	0.7	8
96	Cancer emerging from the recurrence of sessile serrated adenoma/polyp resected endoscopically 5 years ago. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 89-95.	0.6	7
97	A Proposal for Definition of Minimally Invasive Adenocarcinoma of the Lung Regardless of Tumor Size. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1027-1032.	0.7	7
98	RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient. <i>Lung Cancer</i> , 2021, 151, 101-103.	0.9	7
99	Influence of degree of DNA degradation in formalin-fixed and paraffin-embedded tissue samples on accuracy of genome-wide DNA methylation analysis. <i>Epigenomics</i> , 2021, 13, 565-576.	1.0	7
100	Genome-Wide Chromatin Analysis of FFPE Tissues Using a Dual-Arm Robot with Clinical Potential. <i>Cancers</i> , 2021, 13, 2126.	1.7	7
101	Genital ¹²⁵ I-Microglobulin Amyloidoma in a Long-Term Dialysis Patient. <i>American Journal of Kidney Diseases</i> , 2006, 48, e35-e39.	2.1	6
102	Ultrasonographic and non-enhanced CT features of acute transient thyroid swelling following fine-needle aspiration biopsy: report of four cases. <i>Journal of Medical Ultrasonics (2001)</i> , 2015, 42, 417-425.	0.6	6
103	Stromal tiny black dots, like "sugar-coated", of von Kossa stain is a diagnostic clue to hyalinizing trabecular tumor of the thyroid gland. <i>Pathology International</i> , 2018, 68, 176-182.	0.6	6
104	Large pulmonary sclerosing pneumocytoma with massive necrosis and vascular invasion: a case report. <i>Oxford Medical Case Reports</i> , 2019, 2019, .	0.2	6
105	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 793-805.	0.5	6
106	Neuroendocrine Tumors of the Liver and Pancreas Associated with Elevated Serum Prostatic Acid Phosphatase.. <i>Internal Medicine</i> , 1995, 34, 886-891.	0.3	5
107	A Case of Retained Surgical Sponge (gossypiboma) and MR Features.. <i>Japanese Journal of Gastroenterological Surgery</i> , 2000, 33, 1719-1723.	0.0	5
108	Cytokeratin expression profiling is useful for distinguishing between primary squamous cell carcinoma of the lung and pulmonary metastases from tongue cancer. <i>Pathology International</i> , 2010, 60, 575-580.	0.6	5

#	ARTICLE	IF	CITATIONS
109	Hepatoid tenosynovial giant cell tumor – A rare morphologic variant case report. <i>Pathology Research and Practice</i> , 2014, 210, 694-697.	1.0	5
110	Intrathyroidal Epithelial Thymoma: Carcinoma Showing Thymus-like Differentiation Mimicking Squamous Cell Carcinoma of the Thyroid. <i>Journal of Nippon Medical School</i> , 2015, 82, 2-3.	0.3	5
111	Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 795-802.	0.6	5
112	Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites. <i>Gynecologic Oncology</i> , 2020, 157, 398-404.	0.6	5
113	Cytology Reporting System for Lung Cancer from the Japan Lung Cancer Society and the Japanese Society of Clinical Cytology: An Extensive Study Containing More Benign Lesions. <i>Acta Cytologica</i> , 2022, 66, 124-133.	0.7	5
114	A Case of Sjögren's Syndrome with Wegener's Granulomatosis-like Pulmonary Involvement. <i>Allergology International</i> , 2005, 54, 339-342.	1.4	4
115	Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes. <i>BMC Cancer</i> , 2013, 13, 8.	1.1	4
116	Trimodality therapy for superior sulcus tumour: experience of a single institution over 19 years. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 167-173.	0.6	4
117	Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 271-278.	0.6	4
118	Salivary gland-type neoplasm of the lung. <i>Diagnostic Histopathology</i> , 2014, 20, 398-404.	0.2	3
119	A Clinicopathological Analysis of Soft Tissue Sarcoma with Telangiectatic Changes. <i>Sarcoma</i> , 2015, 2015, 1-5.	0.7	3
120	A case of inflammatory hepatocellular adenoma displaying an unusual histological pattern. <i>Clinical Journal of Gastroenterology</i> , 2015, 8, 426-434.	0.4	3
121	Resection of a large ectopic parathyroid adenoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 23, 8-11.	0.2	3
122	Rapidly growing giant cell tumor of bone in a skeletally immature girl. <i>Skeletal Radiology</i> , 2016, 45, 567-573.	1.2	3
123	Two-stage surgery on pregnant woman with a giant cell tumor of bone who refused blood transfusion: A case report. <i>Journal of Orthopaedic Science</i> , 2017, 22, 169-172.	0.5	3
124	Pulmonary artery sarcoma presenting as an isolated lung mass. <i>General Thoracic and Cardiovascular Surgery</i> , 2017, 65, 171-174.	0.4	3
125	P3.02c-097 Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1338-S1339.	0.5	3
126	Lung cancer biomarker tests: the history and perspective in Japan. <i>Translational Lung Cancer Research</i> , 2020, 9, 879-886.	1.3	3

#	ARTICLE	IF	CITATIONS
127	Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, e145-e146.	0.5	3
128	Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib. <i>Lung Cancer</i> , 2021, 151, 1-4.	0.9	3
129	Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9044-9044.	0.8	3
130	Factors predicting the efficacy of gefitinib in patients with advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2005, 23, 7095-7095.	0.8	3
131	Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-“small Cell Lung Cancer PDX Models with Driver Genetic Alterations. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 359-370.	1.9	3
132	Mycosis Fungoides in a Hemodialysis Patient With Intractable Pruritus. <i>Therapeutic Apheresis and Dialysis</i> , 2006, 10, 296-300.	0.4	2
133	The CYVADIC Regimen as a Combination Chemotherapy Treatment Option for Advanced Soft Tissue Sarcomas Originating from the Non-Extremities. <i>Internal Medicine</i> , 2015, 54, 187-193.	0.3	2
134	Cytogenetic study of secondary malignancy in giant cell tumor. <i>Journal of Orthopaedic Science</i> , 2015, 20, 217-223.	0.5	2
135	The new transbronchial diagnostic approach for the metastatic lung tumor from renal cell carcinoma“a case report. <i>Journal of Thoracic Disease</i> , 2017, 9, E762-E766.	0.6	2
136	Prognostic Impact of Tumor Doubling Time in Patients with Metachronous Lung Cancer. <i>World Journal of Surgery</i> , 2019, 43, 3259-3266.	0.8	2
137	The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9046-9046.	0.8	2
138	Cytological evaluation of the “Indeterminate” category by The Bethesda System for Reporting Thyroid Cytopathology. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2014, 53, 251-256.	0.0	2
139	Epithelioid sarcoma cytologic features of two cases.. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 1997, 36, 627-632.	0.0	2
140	ACTN4 gene amplification is a predictive biomarker for adjuvant chemotherapy with UFT in stage I lung adenocarcinomas. <i>Cancer Science</i> , 2021, , .	1.7	2
141	Multiple bronchioloalveolar carcinomas in acromegaly: A potential role of insulin-like growth factor I in carcinogenesis. <i>Lung Cancer</i> , 2006, 54, 247-253.	0.9	1
142	Prognostic impact of bulky swollen lymph nodes in cN1 non-small cell lung cancer patients. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 1050-1054.	0.6	1
143	P3.02-041 EGFR Amplification Mediates Resistance to TAS121, A Third-Generation EGFR-TKI, in EGFR T790M-Positive Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2252.	0.5	1
144	OA03.02 Nationwide Comparative Study Of PD-L1 IHC Assays on Lung Cancer: Initial Report Of LC-SCRUM-IBIS Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, S324-S325.	0.5	1

#	ARTICLE	IF	CITATIONS
145	SMARCB1 deficient squamous cell carcinoma of a mediastinal cyst. Pathology International, 2018, 68, 563-566.	0.6	1
146	Histological and prognostic data on surgically resected early-stage lung adenocarcinoma. Data in Brief, 2020, 31, 105785.	0.5	1
147	Pulmonary microinvasive small cell carcinoma with an extensive <i>in situ</i> component identified after photodynamic therapy for squamous cell carcinoma <i>in situ</i> : a case report. Histopathology, 2021, 78, 912-916.	1.6	1
148	Integrated genomic analysis of lung adenocarcinomas identifies loss of the MAPK phosphatase gene DUSP4 in most EGFR mutant tumors. Journal of Clinical Oncology, 2007, 25, 7686-7686.	0.8	1
149	Feasibility of EBUS-TBNA specimens for PD-L1 expression test in lung cancer.. Journal of Clinical Oncology, 2016, 34, e23112-e23112.	0.8	1
150	A Case of Malignant Pleural Mesothelioma Mimicking Bronchioloalveolar Carcinoma in Its Intrapulmonary Growth Pattern. Japanese Journal of Lung Cancer, 2006, 46, 215-220.	0.0	1
151	A case of inflammatory myofibroblastic tumor diagnosed by thoroscopic resection : A case report. The Journal of the Japanese Society of Clinical Cytology, 2013, 52, 164-168.	0.0	1
152	Two Cases of Synchronous Multiple Lung Cancer Harboring Different Mutations; EGFR or ALK. Japanese Journal of Lung Cancer, 2014, 54, 146-152.	0.0	1
153	Cytological study of six cases of synovial sarcoma.. The Journal of the Japanese Society of Clinical Cytology, 1997, 36, 583-588.	0.0	1
154	Abstract 3542: Abnormal intracytoplasmic accumulation of autophagy-related protein p62/SQSTM1 characterizes giant cells of giant cell tumor of bone. , 2016, , .		1
155	PD1-3-6: Gene expression profiling of large cell neuroendocrine carcinoma (LCNEC). Journal of Thoracic Oncology, 2007, 2, S423.	0.5	0
156	Management and treatment of soft tissue sarcoma patients by medical oncologists in multidisciplinary center. Annals of Oncology, 2015, 26, vii87.	0.6	0
157	Touch cytology smear of an inflammatory hepatocellular adenoma displaying an unusual pattern: A case report. Diagnostic Cytopathology, 2016, 44, 1074-1077.	0.5	0
158	Giant lamellar bodies associated with adenocarcinoma of the lung. Histopathology, 2016, 69, 1090-1092.	1.6	0
159	P3.01-006 Prognostic Impact of Tumor Spread through Air Spaces in Limited Resection for pStage I Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1122.	0.5	0
160	P3.01-015 Prognostic Impact of Histologic Invasion Factors in Pulmonary Adenocarcinoma, with Particular Focus on the Pattern of Architectural Remodeling. Journal of Thoracic Oncology, 2017, 12, S1127-S1128.	0.5	0
161	PUB015 The Use of Immunohistochemistry Improves the Diagnosis of SCLC. An International Reproducibility Study in a Demanding Set of Cases. Journal of Thoracic Oncology, 2017, 12, S1454-S1455.	0.5	0
162	A newly emerged osteosarcomatous dedifferentiation of liposarcoma in lung metastasis –a potential diagnostic pitfall. Pathology International, 2017, 67, 50-52.	0.6	0

#	ARTICLE	IF	CITATIONS
163	P3.02-035 Mutational Signatures and Their Association with Clinicopathological Features in Lung Adenocarcinoma of Smokers. Journal of Thoracic Oncology, 2017, 12, S2250.	0.5	0
164	P3.13-009 Rapid Detection of Lung Cancer by Fluorescent Imaging Using A β -Glutamyltranspeptidase-Activatable Fluorescent Probe. Journal of Thoracic Oncology, 2017, 12, S2318-S2319.	0.5	0
165	Response to Letter to the Editor Titled "Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer" Journal of Thoracic Oncology, 2018, 13, e58-e59.	0.5	0
166	Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: LC-SCRUM-IBIS. Annals of Oncology, 2018, 29, vii52.	0.6	0
167	Immuno-oncology biomarker study in non-small cell lung cancer harboring oncogenic driver alterations: LC-SCRUM-IBIS. Annals of Oncology, 2019, 30, vi113.	0.6	0
168	Correlation between folate receptor alpha (FR α) expression and clinicopathological features in lung adenocarcinoma. Annals of Oncology, 2019, 30, ii2.	0.6	0
169	Squamous differentiation in surgically resected malignant pleural mesothelioma with neoadjuvant chemotherapy. Pathology International, 2021, 71, 692-696.	0.6	0
170	Cytology of tuberculous endometritis - Report of a case.. The Journal of the Japanese Society of Clinical Cytology, 2000, 39, 93-98.	0.0	0
171	Malignant pleural mesothelioma showing a solitary shadow in the lung field-A case report-. The Journal of the Japanese Society of Clinical Cytology, 2011, 50, 115-119.	0.0	0
172	Bronchial granular cell tumor^ ^mdash;a report of two cases^ ^mdash;. The Journal of the Japanese Society of Clinical Cytology, 2012, 51, 354-359.	0.0	0
173	ALK and EGFR mutation analysis in a phase II trial of cisplatin/pemetrexed in Japanese patients with advanced nonsquamous non-small cell lung cancer.. Journal of Clinical Oncology, 2012, 30, e18017-e18017.	0.8	0
174	Presumptive diagnosis of pulmonary PEComa by imprint cytology^ ^mdash;A case report^ ^mdash;. The Journal of the Japanese Society of Clinical Cytology, 2014, 53, 371-376.	0.0	0
175	Abstract 300: Expression profiling of miRNA in asbestos-related lung adenocarcinoma. , 2014, , .		0
176	Cytological evaluation of thyroid cyst. The Journal of the Japanese Society of Clinical Cytology, 2015, 54, 103-106.	0.0	0
177	Case Report: Asymptomatic Osteosarcoma. Case Reports in Clinical Medicine, 2015, 04, 369-375.	0.1	0
178	Risk factors of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.. Journal of Clinical Oncology, 2015, 33, e21527-e21527.	0.8	0
179	Abstract 3853: Unique pattern of copy number changes including chromothripsis in pulmonary adenocarcinoma with EML4-ALK fusion. , 2015, , .		0
180	Imprint cytology of pulmonary artery sarcoma. The Journal of the Japanese Society of Clinical Cytology, 2016, 55, 94-99.	0.0	0

#	ARTICLE	IF	CITATIONS
181	Prognostic value of CD8+ tumor-infiltrating lymphocyte density and PD-L1 expression in tumor cells in thymic epithelial tumors.. Journal of Clinical Oncology, 2017, 35, 21-21.	0.8	0
182	Stromal infiltrating CD8+ and CD20+ lymphocytes and CD204+ M2 macrophages but not PD-L1 expression on tumor cells are prognosticators for patients with resectable thymic carcinoma.. Journal of Clinical Oncology, 2017, 35, e20002-e20002.	0.8	0
183	Abstract 4260: Increased mutation burden in normal-appearing lung tissues with high cancer risk. , 2017, , .		0
184	A case of myoepithelial carcinoma of the left shoulder. The Journal of the Japanese Society of Clinical Cytology, 2018, 57, 129-135.	0.0	0
185	An Update of Companion Diagnostics for Lung Cancer. Japanese Journal of Lung Cancer, 2018, 58, 77-82.	0.0	0
186	Immuno-oncology biomarker study in a large cohort of LC-SCRUM-Japan: Assessment of PD-L1 expression and tumor mutation burden in non-small cell lung cancer patients treated with immune checkpoint inhibitors.. Journal of Clinical Oncology, 2018, 36, 9070-9070.	0.8	0
187	Feasibility study of cryobiopsy for practical pathological diagnosis including immunohistochemical assessment of primary lung cancer. , 2018, , .		0
188	Neuroendocrine Tumor of Lung and Mediastinum: the Updated Pathological Diagnosis and Treatment. Japanese Journal of Lung Cancer, 2019, 59, 37-45.	0.0	0
189	Assessment of PD-L1 expression and oncogenic gene status in patients with small-cell lung cancer: Immuno-oncology biomarker study in LC-SCRUM-Japan.. Journal of Clinical Oncology, 2019, 37, 8558-8558.	0.8	0
190	Abstract 4919: Required numbers of biopsy samples and tumor cells for the assessment of PD-L1 expression to predict a response to nivolumab treatment in patients with NSCLC. , 2019, , .		0
191	Osteosarcoma arising from acetabulum extended to femoral head through round ligament: a case report. Oxford Medical Case Reports, 2020, 2020, omaa076.	0.2	0
192	The combined use of long non-coding RNA HOTAIR and polycomb group protein EZH2 as a prognostic marker of lung adenocarcinoma. Cancer Treatment and Research Communications, 2022, 31, 100541.	0.7	0